Business
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial a
About this update from Sight Sciences, Inc.
[{"type":"image","alt":"Sight Sciences, Inc.","displaySize":"","headline":null,"caption":"Sight Sciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iWYluxF6m_THbwAGSEG.kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971","width":300,"height":106}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025.","length":481,"tagName":"p"},{"type":"text","content":"Recent Financial and Business Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company’s Surgical Glaucoma revenue increased 6% compared to the same period in the prior year, offset by the expected decline in revenue from the Company’s Dry Eye segment, which decreased 88% compared to the third quarter of 2024 as result of the Company’s focus on efforts to achieve reimbursed market access. ","length":441,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced total operating expenses to $25.1 million in the third quarter of 2025, representing an 11% decrease compared to $28.1 million in the same period in the prior year. Operating expenses included $2.8 million in restructuring costs associated with the reduction in force announced on August 27, 2025. ","length":305,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased Surgical Glaucoma ordering accounts to an all-time high of 1,197 accounts, up 8% compared to the third quarter of 2024. ","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer...